Date:2/26/2013

ersus placebo). The objectives of the study primarily were to evaluate safety and tolerability, effects on sputum inflammatory markers, and lung function after a single dose of KB002. KB002 was found to be generally safe and well tolerated. Mean FEV₁ value for the active treatment group increased 120ml from baseline to day 42 and decreased 40ml for the placebo group. Of the 24 subjects enrolled (17 on KB002 and 7 on placebo), 59% on KB002 versus 29% on placebo had a >100ml FEV₁ increase at day 42. In addition, when patients were segmented retrospectively by the criteria of "reversibility," with reversible patients defined as having a >12% improvement in FEV₁ from baseline after a beta agonist, reversible patients on KB002 experienced a greater increase in FEV₁ from baseline at day 42 versus those on placebo. A majority of responders showed an FEV₁ improvement of more than 10%, which is a level that is generally accepted as clinically meaningful. At day 42, 78% of KB002-treated reversible subjects had at least a 100-mL increase in FEV₁ compared with 38% of KB002-treated nonreversible subjects, 33% of placebo-treated reversible subjects, and 25% of placebo-treated nonreversible subjects. A majority of KB002-treated patients who had an improvement in FEV₁ also had measureable antibody in the sputum in addition to a decrease in eosinophils or neutrophils at day 28.

About KB002/ KB003

KB002 and KB003 are recombinant monoclonal antibodies designed to target and neutralize human granulocyte macrophage colony-stimulating factor (GM-CSF), with potential for use in inflammatory and autoimmune indications. GM-CSF is an important part of an inflammatory cascade that stimulates white blood cells (granulocytes, including eosinophils, neutrophils, and macrophages) and maintains them in an active state.  However, as described in a number of scientific publications, excess
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
2. KaloBios Pharmaceuticals Completes Initial Public Offering
3. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
4. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
5. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
6. Dr. Diana Bianchi Presents Data Demonstrating Verinata Healths Proprietary Technology Detects Genetic Abnormalities In Twin Pregnancies
7. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
8. Misonix Presents at MicroCapClub Invitational
9. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
10. Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment
11. Peripheral Vascular Devices Market to 2018 - Increasing Demand for Minimally Invasive Endovascular Procedures Presents Growth Opportunities for Manufacturers